-
肺癌是世界上发病率和病死率最高的恶性肿瘤之一[1],其中非小细胞肺癌(non-small cell lung cancer,NSCLC)占肺癌患者总数的85%[2]。据美国癌症学会统计数据显示,NSCLC患者5年生存率仅为18%[3]。准确的预后评估,是选择个体化治疗方案的先决条件,也是提高患者生存率及生活质量的必备条件。目前,对于NSCLC的影像学诊断及评估主要基于传统显像模式,包括CT及MRI。传统显像模式一方面主要依赖于病灶形态学变化,无法提供代谢相关信息;另一方面,显像部位局限,无法同时提供全身其他转移病灶信息。而PET/CT可同时显示分子水平的全身代谢信息及肿瘤的形态特征,特别是18F-FDG PET/CT,在NSCLC的分期、治疗规划及疗效监测中均有重要价值[4],通过18F-FDG PET/CT半定量参数测定,包括SUV、肿瘤代谢体积(metabolic tumor volume,MTV)及病灶糖酵解总量(total lesion glycolysis,TLG),可为NSCLC提供良好的预后评估[5-7]。笔者就近年来上述代谢半定量参数在NSCLC的预后评估中的价值作一综述。
-
18F-FDG PET/CT代谢半定量参数主要包括SUV、MTV和TLG。其中,SUV为半定量指标,是18F-FDG PET/CT显像中最常用的代谢活性参数,其主要包括SUVmax和平均标准化摄取值(mean standardized uptake value, SUVmean);MTV和TLG是反映肿瘤负荷的代谢参数。关于18F-FDG PET/CT代谢半定量参数及其影响因素的具体情况详见表 1。
代谢半定量参数 定义 公式 意义 影响因素 应用 SUV 局部组织摄取显像剂的放射性活度与全身平均注射活度的比值 SUV=局部组织的18F-FDG放射性活度(Bq/g)/(注射的18F-FDG放射性活度/体重)(Bq/g) 包括SUVmax和SUVmean等,SUVmax反映划定区域内最活跃的糖代谢水平,SUVmean反映划定区域内平均糖代谢水平 SUVmean受划定区域的影响较大;部分容积效应、图像分辨率、重建方法、噪声比、对比剂与受试的时间间隔、衰减校正、标准化因素以及血浆内的葡萄糖代谢水平等[11-12] 应用于临床工作及科研 MTV 肿瘤代谢体积,即感兴趣区内大于SUV分界值的所有肿瘤体积之和 - 可同时反映肿瘤代谢体积及肿瘤代谢负担 分界值的采用(大于2.5[13]或大于SUVmax的50%[14]),不同的研究采用分界值不同;恶性病灶的边缘划定,如脑转移瘤[15] 主要应用于科研 TLG 肿瘤糖代谢量总和 TLG=MTV×SUVmean 可反映病灶葡萄糖代谢总量 同MTV 主要应用于科研 注:表中,“原”表示此项无计算公式;SUV:标准化摄取值;SUVmax:最大标准化摄取值;SUVmean:平均标准化摄取值;MTV:肿瘤代谢体积;TLG:病灶糖酵解总量。 表 1 18F-FDG PET/CT代谢半定量参数及其影响因素
Table 1. Semi-quantitative metabolic parameters of 18F-FDG PET/CT and the related impact factors
18F-FDG PET/CT代谢半定量参数在非小细胞肺癌预后评估中的价值
Prognostic evaluation of patients with non-small cell lung cancer by using semi-quantitative metabolic parameters of 18F-FDG PET/CT
-
摘要: 准确的预后评估对于非小细胞肺癌(NSCLC)治疗方案的选择至关重要。18F-FDG PET/CT可同时提供功能显像及解剖学显像信息,在NSCLC患者的诊疗过程,尤其是在NSCLC患者的预后评估方面起着重要作用。笔者主要就近年来18F-FDG PET/CT代谢半定量参数在NSCLC患者预后评估中的价值进行综述。
-
关键词:
- 癌,非小细胞肺 /
- 正电子发射断层显像计算机体层摄影术 /
- 氟脱氧葡萄糖F18 /
- 预后
Abstract: Accurate diagnosis and prognostic evaluation are essential for the management of patients with non-small cell lung cancer(NSCLC). PET/CT, as a new imaging modality which can provide functional and anatomical imaging simultaneously, plays an important role in theranostics of these patients. This review focuses on the prognostic evaluation of patients with NSCLC by using semi-quantitative metabolic parameters of 18F-FDG PET/CT. -
表 1 18F-FDG PET/CT代谢半定量参数及其影响因素
Table 1. Semi-quantitative metabolic parameters of 18F-FDG PET/CT and the related impact factors
代谢半定量参数 定义 公式 意义 影响因素 应用 SUV 局部组织摄取显像剂的放射性活度与全身平均注射活度的比值 SUV=局部组织的18F-FDG放射性活度(Bq/g)/(注射的18F-FDG放射性活度/体重)(Bq/g) 包括SUVmax和SUVmean等,SUVmax反映划定区域内最活跃的糖代谢水平,SUVmean反映划定区域内平均糖代谢水平 SUVmean受划定区域的影响较大;部分容积效应、图像分辨率、重建方法、噪声比、对比剂与受试的时间间隔、衰减校正、标准化因素以及血浆内的葡萄糖代谢水平等[11-12] 应用于临床工作及科研 MTV 肿瘤代谢体积,即感兴趣区内大于SUV分界值的所有肿瘤体积之和 - 可同时反映肿瘤代谢体积及肿瘤代谢负担 分界值的采用(大于2.5[13]或大于SUVmax的50%[14]),不同的研究采用分界值不同;恶性病灶的边缘划定,如脑转移瘤[15] 主要应用于科研 TLG 肿瘤糖代谢量总和 TLG=MTV×SUVmean 可反映病灶葡萄糖代谢总量 同MTV 主要应用于科研 注:表中,“原”表示此项无计算公式;SUV:标准化摄取值;SUVmax:最大标准化摄取值;SUVmean:平均标准化摄取值;MTV:肿瘤代谢体积;TLG:病灶糖酵解总量。 -
[1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108. DOI:10.3322/caac.21262. [2] Vansteenkiste J, Crinò L, Dooms C, et al. 2nd ESMO Consensus Conference on Lung Cancer:early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up[J]. Ann Oncol, 2014, 25(8):1462-1474. DOI:10.1093/annonc/mdu089. [3] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1):7-30. DOI:10.3322/caac.21387. [4] Grootjans W, de Geus-Oei LF, Troost EG, et al. PET in the management of locally advanced and metastatic NSCLC[J]. Nat Rev Clin Oncol, 2015, 12(7):395-407. DOI:10.1038/nrclinonc.2015.75. [5] Ohtaka K, Hida Y, Kaga K, et al. Outcome analysis of 18F-fluorodeoxyglucose positron-emission tomography in patients with lung cancer after partial volume correction[J]. Anticancer Res, 2013, 33(11):5193-5198. [6] Ohri N, Duan F, Machtay M, et al. Pretreatment FDG-PET metrics in stage Ⅲ non-small cell lung cancer: ACRIN 6668/RTOG 0235[J]. J Natl Cancer Inst, 2015, 107(4): djv004[2018-02-23]. https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4402361. DOI:10.1093/jnci/djv004. [7] Ooi H, Chen CY, Hsiao YC, et al. Fluorodeoxyglucose Uptake in Aadvanced Non-small Cell Lung Cancer With and Without Pulmonary Lymphangitic Carcinomatosis[J]. Anticancer Res, 2016, 36(8):4313-4320. [8] Tian M, Zhang H, Nakasone Y, et al. Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study[J]. Eur J Nucl Med Mol Imaging, 2004, 31(1):5-12. DOI:10.1007/s00259-003-1316-9. [9] Okada M, Tauchi S, Iwanaga K, et al. Associations among bronchioloalveolar carcinoma components, positron emission tomographic and computed tomographic findings, and malignant behavior in small lung adenocarcinomas[J]. J Thorac Cardiovasc Surg, 2007, 133(6):1448-1454. DOI:10.1016/j.jtcvs.2007.02.023. [10] Novello S, Giaj LM, Vavalà T. Functional imaging in predicting response to antineoplastic agents and molecular targeted therapies in lung cancer: a review of existing evidence[J]. Crit Rev Oncol Hematol, 2012, 83(2):208-215. DOI:10.1016/j.critrevonc. 2011. 09. 009. [11] Boellaard R, Krak NC, Hoekstra OS, et al. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values:a simulation study[J]. J Nucl Med, 2004, 45(9):1519-1527. [12] Westerterp M, Pruim J, Oyen W, et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials:effects of image reconstruction, resolution and ROI definition parameters[J]. Eur J Nucl Med Mol Imaging, 2007, 34(3):392-404. DOI:10.1007/s00259-006-0224-1. [13] Yan H, Wang R, Zhao F, et al. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy[J]. Acta Radiol, 2011, 52(6):646-650. DOI:10.1258/ar.2011.100462. [14] Chen HH, Chiu NT, Su WC, et al. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer[J]. Radiology, 2012, 264(2):559-566. DOI:10.1148/radiol.12111148. [15] Ludwig V, Komori T, Kolb D, et al. Cerebral lesions incidentally detected on 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography images of patients evaluated for body malignancies[J]. Mol Imaging Biol, 2002, 4(5):359-362. DOI:10.1016/S1536-1632(02)00024-0. [16] Domachevsky L, Groshar D, Galili R, et al. Survival Prognostic Value of Morphological and Metabolic Variables in Patients with Stage Ⅰ and Ⅱ Non-Small Cell Lung Cancer[J]. Eur Radiol, 2015, 25(11):3361-3367. DOI:10.1007/s00330-015-3754-8. [17] Agarwal M, Brahmanday G, Bajaj SK, et al. Revisiting the prognostic value of preoperative 18F-fluoro-2-deoxyglucose 18F-FDG positron emission tomography (PET) in early-stage (Ⅰ & Ⅱ) non-small cell lung cancers (NSCLC)[J]. Eur J Nucl Med Mol Imaging, 2010, 37(4):691-698. DOI:10.1007/s00259-009-1291-x. [18] Goodgame B, Pillot GA, Yang Z, et al. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer[J]. J Thorac Oncol, 2008, 3(2):130-134. DOI:10.1097/JTO.0b013e318160c122. [19] Hanin FX, Lonneux M, Cornet J, et al. Prognostic value of FDG uptake in early stage non-small cell lung cancer[J]. Eur J Cardiothorac Surg, 2008, 33(5):819-823. DOI:10.1016/j.ejcts.2008. 02.005. [20] Yoo IeR, Chung SK, Park HL, et al. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis[J]. Biomed Mater Eng, 2014, 24(6):3091-3103. DOI:10.3233/BME-141131. [21] Korkmaz T, Seber S, Okutur K, et al. Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer[J]. Biomarkers, 2013, 18(1):88-94. DOI:10.3109/1354750X.2012.738250. [22] Lin MY, Wu M, Brennan S, et al. Absence of a relationship between tumor 18F-fluorodeoxyglucose standardized uptake value and survival in patients treated with definitive radiotherapy for non-small-cell lung cancer[J]. J Thorac Oncol, 2014, 9(3):377-382. DOI:10.1097/JTO.0000000000000096. [23] Jin F, Zhu H, Fu Z, et al. Prognostic value of the standardized uptake value maximum change calculated by dual-time-point 18F-fluorodeoxyglucose positron emission tomography imaging in patients with advanced non-small-cell lung cancer[J]. Onco Targets Ther, 2016, 9:2993-2999. DOI:10.2147/OTT.S104919. [24] Billè A, Okiror L, Skanjeti A, et al. The prognostic significance of maximum standardized uptake value of primary tumor in surgically treated non-small-cell lung cancer patients:analysis of 413 cases[J]. Clin Lung Cancer, 2013, 14(2):149-156. DOI:10.1016/j.cllc.2012. 04.007. [25] Hyun SH, Choi JY, Kim K, et al. Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection[J]. Ann Surg, 2013, 257(2):364-370. DOI:10.1097/SLA.0b013e318262a6ec. [26] Hyun SH, Ahn HK, Ahn MJ, et al. Volume-Based Assessment with 18F-FDG PET/CT Improves Outcome Prediction for Patients with Stage ⅢA-N2 Non-Small Cell Lung Cancer[J]. AJR Am J Roentgenol, 2015, 205(3):623-628. DOI:10.2214/AJR.14.13847. [27] Zhang H, Wroblewski K, Jiang Y, et al. A new PET/CT volumetric prognostic index for non-small cell lung cancer[J]. Lung Cancer, 2015, 89(1):43-49. DOI:10.1016/j.lungcan.2015.03.023. [28] Ohri N, Piperdi B, Garg MK, et al. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage Ⅲ non-small cell lung cancer[J]. Lung Cancer, 2015, 87(1):23-27. DOI:10.1016/j.lungcan.2014.10.016. [29] Huang W, Liu B, Fan M, et al. The early predictive value of a decrease of metabolic tumor volume in repeated 18F-FDG PET/CT for recurrence of locally advanced non-small cell lung cancer with concurrent radiochemotherapy[J]. Eur J Radiol, 2015, 84(3):482-488. DOI:10.1016/j.ejrad.2014.11.020. [30] Han EJ, Yang YJ, Park JC, et al. Prognostic value of early response assessment using 18F-FDG PET/CT in chemotherapy-treated patients with non-small-cell lung cancer[J]. Nucl Med Commun, 2015, 36(12):1187-1194. DOI:10.1097/MNM.0000000000000382. [31] Huang W, Fan M, Liu B, et al. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy[J]. J Nucl Med, 2014, 55(10):1584-1590. DOI:10.2967/jnumed.114.142919. [32] Melloni G, Gajate AM, Sestini S, et al. New positron emission tomography derived parameters as predictive factors for recurrence in resected stageⅠnon-small cell lung cancer[J]. Eur J Surg Oncol, 2013, 39(11):1254-1261. DOI:10.1016/j.ejso.2013.07.092. [33] Park SY, Cho A, Yu WS, et al. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage ⅠA non-small cell lung cancer[J]. J Nucl Med, 2015, 56(1):45-49. DOI:10.2967/jnumed.114.147561. [34] Moon SH, Cho SH, Park LC, et al. Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy[J]. Eur J Nucl Med Mol Imaging, 2013, 40(7):1005-1013. DOI:10.1007/s00259-013-2400-4. [35] Soussan M, Chouahnia K, Maisonobe JA, et al. Prognostic implications of volume-based measurements on FDG PET/CT in stage Ⅲ non-small-cell lung cancer after induction chemotherapy[J]. Eur J Nucl Med Mol Imaging, 2013, 40(5):668-676. DOI:10.1007/s00259-012-2321-7. [36] Usmanij EA, de Geus-Oei LF, Troost EG, et al. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy[J]. J Nucl Med, 2013, 54(9):1528-1534. DOI:10.2967/jnumed.112.116921. [37] Keam B, Lee SJ, Kim TM, et al. Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation[J]. J Thorac Oncol, 2015, 10(8):1189-1194. DOI:10.1097/JTO.000000000000- 0569. [38] 张佳胤, 李彪.正电子药物在肿瘤诊断中的进展[J].国际放射医学核医学杂志, 2006, 30(1):30-35. DOI:10.3760/cma.j.issn.1673-4114.2006.01.011.
Zhang JY, Li B. The development of positron emission tomography tracers in the diagnosis of malignant tumors[J]. Int J Radiat Med Nucl Med, 2006, 30(1):30-35. doi: 10.3760/cma.j.issn.1673-4114.2006.01.011